Keiichi Sumida1, Miklos Z Molnar, Praveen K Potukuchi, Fridtjof Thomas, Jun Ling Lu, Kunihiro Yamagata, Kamyar Kalantar-Zadeh, Csaba P Kovesdy. 1. aDivision of Nephrology, Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA bNephrology Center, Toranomon Hospital Kajigaya, Kawasaki, Kanagawa cDepartment of Nephrology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan dDepartment of Transplantation and Surgery, Semmelweis University, Budapest, Hungary eDivision of Biostatistics, Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, Tennessee fDivision of Nephrology and Hypertension, Harold Simmons Center for Chronic Disease Research and Epidemiology, University of California-Irvine, Orange, California gNephrology Section, Memphis VA Medical Center, Memphis, Tennessee, USA.
Abstract
OBJECTIVES: Higher SBP visit-to-visit variability (SBPV) has been associated with increased risk of adverse events in patients with chronic kidney disease, but the association of SBPV in advanced nondialysis-dependent chronic kidney disease with mortality after the transition to end-stage renal disease (ESRD) remains unknown. METHODS: Among 17 729 US veterans transitioning to dialysis between October 2007 and September 2011, we assessed SBPV calculated from the SD of at least three intraindividual outpatient SBP values during the last year prior to dialysis transition (prelude period). Outcomes included factors associated with higher prelude SBPV and post-transition all-cause, cardiovascular, and infection-related mortality, assessed using multivariable linear regression and Cox and competing risk regressions, respectively, adjusted for demographics, comorbidities, medications, cardiovascular medication adherence, SBP, BMI, estimated glomerular filtration rate, and type of vascular access. RESULTS: Modifiable clinical factors associated with higher prelude SBPV included higher SBP, use of antihypertensive medications and erythropoiesis-stimulating agents, inadequate cardiovascular medication adherence, and catheter use. After multivariable adjustment, higher prelude SBPV was significantly associated with higher post-ESRD all-cause and infection-related mortality, but not cardiovascular mortality [hazard/subhazard ratios (95% confidence interval) for the highest (vs. lowest) quartile of SBPV, 1.08 (1.01-1.16), 1.02 (0.89-1.15), and 1.41 (1.10-1.80) for all-cause, cardiovascular, and infection-related mortality, respectively]. CONCLUSION: High pre-ESRD SBPV is potentially modifiable and associated with higher all-cause and infection-related mortality following dialysis initiation. Further studies are needed to test whether modification of pre-ESRD SBPV can improve clinical outcomes in incident ESRD patients. VIDEO ABSTRACT:.
OBJECTIVES: Higher SBP visit-to-visit variability (SBPV) has been associated with increased risk of adverse events in patients with chronic kidney disease, but the association of SBPV in advanced nondialysis-dependent chronic kidney disease with mortality after the transition to end-stage renal disease (ESRD) remains unknown. METHODS: Among 17 729 US veterans transitioning to dialysis between October 2007 and September 2011, we assessed SBPV calculated from the SD of at least three intraindividual outpatientSBP values during the last year prior to dialysis transition (prelude period). Outcomes included factors associated with higher prelude SBPV and post-transition all-cause, cardiovascular, and infection-related mortality, assessed using multivariable linear regression and Cox and competing risk regressions, respectively, adjusted for demographics, comorbidities, medications, cardiovascular medication adherence, SBP, BMI, estimated glomerular filtration rate, and type of vascular access. RESULTS: Modifiable clinical factors associated with higher prelude SBPV included higher SBP, use of antihypertensive medications and erythropoiesis-stimulating agents, inadequate cardiovascular medication adherence, and catheter use. After multivariable adjustment, higher prelude SBPV was significantly associated with higher post-ESRD all-cause and infection-related mortality, but not cardiovascular mortality [hazard/subhazard ratios (95% confidence interval) for the highest (vs. lowest) quartile of SBPV, 1.08 (1.01-1.16), 1.02 (0.89-1.15), and 1.41 (1.10-1.80) for all-cause, cardiovascular, and infection-related mortality, respectively]. CONCLUSION: High pre-ESRD SBPV is potentially modifiable and associated with higher all-cause and infection-related mortality following dialysis initiation. Further studies are needed to test whether modification of pre-ESRD SBPV can improve clinical outcomes in incident ESRDpatients. VIDEO ABSTRACT:.
Authors: Csaba P Kovesdy; Ahmed Alrifai; Elvira O Gosmanova; Jun Ling Lu; Robert B Canada; Barry M Wall; Adriana M Hung; Miklos Z Molnar; Kamyar Kalantar-Zadeh Journal: Clin J Am Soc Nephrol Date: 2016-04-21 Impact factor: 8.237
Authors: Chenkai Wu; Michael G Shlipak; Robert S Stawski; Carmen A Peralta; Bruce M Psaty; Tamara B Harris; Suzanne Satterfield; Eric J Shiroma; Anne B Newman; Michelle C Odden Journal: Am J Hypertens Date: 2016-09-06 Impact factor: 2.689
Authors: Tariq Shafi; Stephen M Sozio; Karen J Bandeen-Roche; Patti L Ephraim; Jason R Luly; Wendy L St Peter; Aidan McDermott; Julia J Scialla; Deidra C Crews; Navdeep Tangri; Dana C Miskulin; Wieneke M Michels; Bernard G Jaar; Charles A Herzog; Philip G Zager; Klemens B Meyer; Albert W Wu; L Ebony Boulware Journal: J Am Soc Nephrol Date: 2014-01-02 Impact factor: 10.121
Authors: Y Hata; H Muratani; Y Kimura; K Fukiyama; Y Kawano; T Ashida; M Yokouchi; Y Imai; T Ozawa; J Fujii; T Omae Journal: J Hum Hypertens Date: 2002-02 Impact factor: 3.012
Authors: Daichi Shimbo; Jonathan D Newman; Aaron K Aragaki; Michael J LaMonte; Anthony A Bavry; Matthew Allison; JoAnn E Manson; Sylvia Wassertheil-Smoller Journal: Hypertension Date: 2012-07-02 Impact factor: 10.190
Authors: Paul Muntner; Jeff Whittle; Amy I Lynch; Lisandro D Colantonio; Lara M Simpson; Paula T Einhorn; Emily B Levitan; Paul K Whelton; William C Cushman; Gail T Louis; Barry R Davis; Suzanne Oparil Journal: Ann Intern Med Date: 2015-09-01 Impact factor: 25.391
Authors: Bruce M Robinson; Jinyao Zhang; Hal Morgenstern; Brian D Bradbury; Leslie J Ng; Keith P McCullough; Brenda W Gillespie; Raymond Hakim; Hugh Rayner; Joan Fort; Tadao Akizawa; Francesca Tentori; Ronald L Pisoni Journal: Kidney Int Date: 2013-06-26 Impact factor: 10.612